Tarsus Pharmaceuticals has acquired Alkeus for up to $800 million, gaining access to a promising therapy for Stargardt disease currently in late-stage testing. This acquisition highlights the potential value of innovative treatments in the rare eye disease space.

Stargardt Disease. American Academy of Ophthalmology. Macula. American Academy of Ophthalmology. Vision Loss, Central. MedlinePlus. Stargardt macular degeneration. National Cancer Institute. Choroid. MedlinePlus. Choroideremia. National Organization of Rare Disorders. Choroideremia. U.S. Food & Drug Administration. FDA approves novel gene therapy to treat patients with a rare form of inherited ... Stargardt Disease. American Academy of Ophthalmology. Macula. American Academy of Ophthalmology. Vision Loss, Central. MedlinePlus. Stargardt macular degeneration. National Cancer Institute. Choroid. MedlinePlus. Choroideremia. National Organization of Rare Disorders. Choroideremia. U.S. Food & Drug Administration. FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss. This gene is associated with several IRDs, including retinitis pigmentosa. Other therapies in development include medications that prevent the death of cells in the eyes and prosthetics that are implanted into the eye to restore vision. Sources: PreventBlindness.org. Eye Diseases & Con... + 13 · PreventBlindness.org. Eye Diseases & Conditions: Inherited Retinal Diseases. Why family medical history matters to the health of your eyes.How your genetics can affect your vision ... Get a look at the healthcare providers you may work with if you are living with an inherited retinal disease (IRD).The specialists and therapies that treat IRDs Keep in mind that this is a simplified explanation of this condition—there are more than 60 different genes that can be involved in the development of RP, there are numerous subtypes of RP, the disease can follow different patterns, and it can occur as a result of multiple other genetic disorders. It’s estimated that RP affects one out of every 3,000 or 4,000 people. This inherited retinal disease is the most common form of juvenile macular degeneration and symptoms typically begin in late childhood or young adulthood.

City has secured nearly $100 million to advance its next-generation RNAi drugs, including a clotting disorder treatment currently in early human testing. An experimental therapy for Stargardt disease is also on the horizon.

The regulatory progress for AAVantgarde’s AAVB-039 underscores advances in dual-vector gene therapy, as well as scalable manufacturing and efficient rare-disease clinical development. The designation of AAVB-039 as an orphan drug provides several development incentives in the United States, including tax credits for qualified clinical testing, waived FDA application fees, and —if the therapy is ultimately approved—seven years of market exclusivity (1). These incentives not only reduce development risk but also encourage investment in manufacturing platforms for gene therapies targeting rare diseases. Italy-based AAVantgarde Bio, a clinical-stage biotechnology company specializing in therapies for inherited retinal diseases, has achieved two key regulatory milestones for its lead gene therapy program, AAVB-039, in development for treating Stargardt disease. The company announced on Oct. 2, 2025 that it was granted orphan drug designation by FDA and received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its clinical trial authorization (CTA) application (1). AAVB-039 is currently being assessed in a Phase I/II trial (CELESTE), which is designed to evaluate safety, tolerability, and preliminary efficacy across three dose levels in patients with Stargardt disease. Recruitment for an observational study (STELLA) also continues. This study provides important natural history data to inform long-term therapeutic evaluation. The broader impact for the biopharmaceutical industry lies in the validation of strategies to develop therapies for rare inherited disorders for which manufacturing complexity has been a limiting factor. Stargardt disease results from ABCA4 gene mutations, necessitating innovative vector designs for effective gene therapy delivery. Regulatory incentives, such as tax credits and market exclusivity, reduce development risks and encourage investment in rare disease therapies.

A new study identifies key factors influencing vision-related quality of life in patients with recessive Stargardt disease. The findings could inform future therapeutic strategies and patient support initiatives.